Data as of Jul 22
| +1.15 / +2.13%|
The 6 analysts offering 12-month price forecasts for Alnylam Pharmaceuticals Inc have a median target of 97.50, with a high estimate of 110.00 and a low estimate of 65.00. The median estimate represents a +76.44% increase from the last price of 55.26.
The current consensus among 7 polled investment analysts is to Buy stock in Alnylam Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.